Abstract
Magnetic nanoparticles (MNPs) and carbon nanotubes (CNTs) have emerged as two new classes of nanomaterials for simultaneous diagnostics and treatment (theranostics) of cancer. On one hand, MNPs can act as magnetic resonance imaging (MRI) contrast agents, magnetically-driven drug delivery cargoes, filtrations and selective separations of biological entities agents and magnetic fluid hyperthermia (MFH) treatments.[1] On the other hand, CNTs have been used against cancer as intracellular carriers for biologically relevant species[2] thanks to their large surface area and their faculty to penetrate cells or as infrared hyperthermia agents[3], among other possibilities.[4] In order to combine the advantages of both parts, we synthesized in our group a hybrid composed of metallic iron nanoparticles filled in multiwall carbon nanotubes (Fe@CNTs) bioconjugated to the monoclonal antibody (mAb) Cetuximab. CNTs graphitic layers offers a protection against oxidation of iron nanoparticles, keeping them in more magnetically active phases whereas mAb targets epidermal growth factor receptor (EGFR) overexpressing A431 cancer cells. In a pilot study, we showed the in vitro efficiency of Fe@CNTs in selective targeting and elimination of A431 cells over control cell lines via magnetic filtration and hyperthermia.[5] We then studied in detail various Fe@CNTs possessing different phases of iron, in order to correlate their structural and magnetic properties onto their biological performances.[6] In parallel we developed seminal work[7]led by our team about H-bonded supramolecular polymer (SMP) able to wrap around CNTs to exploit the potential of our Fe@CNTs as a non-covalent scaffold. We thus synthesized new pegylated H-bonded supramolecular polymers able to solubilize Fe@CNTs in aqueous media. Moreover, this polymer-CNTs nano-assembly shows interesting properties of reversible wrapping and un-wrapping under thermal stimulus, and is envisaged to be used for simultaneous MFH and triggered drug delivery treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
